ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1214

In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis

Sandhya shri Kannayiram1 and Shilpa Arora2, 1John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, interstitial lung disease, Mortality, Outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Several autoimmune diseases (AD) may be associated with interstitial lung disease (ILD), contributing to increased morbidity and mortality in these patients. We aimed to study the risk of ILD in different ADs and the impact of ILD on the outcomes of AD hospitalized patients utilizing the national inpatient sample database.

Methods: We used the national inpatient sample of 2016-2019 to identify patients with a concomitant discharge diagnosis of ILD and AD [systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SS), Sjogren’s syndrome (SJ), dermato-polymyositis (DM/PM), ANCA associated vasculitis (ANCA-V) or mixed connective tissue disorder (MCTD)] using ICD-10 codes. We divided patients into AD with ILD (AD+ILD) and AD without ILD (AD-ILD) groups. The two groups were compared for baseline characteristics, comorbidities, and outcomes. Univariate and multivariate regression analyses were done. We also calculated the odds of ILD in different ADs among all adult hospitalizations. 

Results: Of 1,153,815 AD hospitalizations, 70,140 (6.1%) patients had concomitant ILD. Patients in the AD+ILD group were more likely to be older (mean age 63.8 vs 57.4 years), females (78.2% vs 21.7 %), Black (23.9% vs 22.8%)/ Hispanic ethnicity (12.8% vs 11.3%), and less likely to be Whites (56.2% vs 60.3%) than those in the AD-ILD group. TAD patients with ILD had higher rates of comorbid coronary artery disease (21% vs 17%), Obstructive sleep apnea(14% vs 9%), supplemental oxygen dependance (27.8% vs 4.6%) and pulmonary hypertension ( 3.9% vs 0.5%).The proportion of different ADs in AD+ILD hospitalizations is depicted in figure 1 and the odds of ILD in different ADs are depicted in Table 1. 4115 (2.5%) AD patients with ILD died during hospitalization (aOR=1.97, 95% CI=1.81 -2.15, p< 0.0001*). AD patients hospitalized with ILD were more likely to have secondary complications such as pneumonia (aOR 1.89, 95% CI 1.81-1.98), sepsis (aOR=1.23, 95% CI=1.14 -1.33), acute right heart failure (aOR 2.41, 95% CI 1.7-3.27), acute respiratory failure (aOR 2.9, 95% CI 2.78-3.05) and required mechanical ventilation (aOR 1.54, 95% CI 1.43-1.67) [p< 0.0001*]. ILD hospitalizations in ADs incurred higher hospitalization charges ($78,0006 vs $64,712) and longer length of stay (6.5days vs 5.4 days, p < 0.0001*).

Conclusion: SLE and systemic sclerosis were the most common ADs in adult ILD hospitalizations. ILD increased the risk of mortality by 2-fold in AD hospitalizations, along with several other complications and increased economic burden. Therefore, early recognition and treatment of ILD are recommended in ADs. 

Supporting image 1

Proportion of different autoimmune diseases in AD with ILD patients.

Supporting image 2

Association of Autoimmune diseases with ILD.


Disclosures: S. Kannayiram, None; S. Arora, None.

To cite this abstract in AMA style:

Kannayiram S, Arora S. In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/in-hospital-outcomes-of-autoimmune-diseases-complicated-by-interstitial-lung-disease-a-national-inpatient-sample-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-hospital-outcomes-of-autoimmune-diseases-complicated-by-interstitial-lung-disease-a-national-inpatient-sample-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology